GHRP-6 for Health & Longevity - Quick Reference Sheet
evipedia.ai ← Back

GHRP-6 for Health & Longevity

Created on 07/02/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 – Audit

GHRP-6 is a synthetic peptide that prompts the body to release its own growth hormone via the hunger-hormone receptor. Its reliable human effects are a short growth-hormone pulse and a strong, brief surge in appetite. Tissue-protection, recovery, and body-composition claims rest on animal data. It is an unapproved research chemical with uncertain purity and no long-term human safety data. (Full Review)

Protocol

Dose
~100 µg subcutaneous
Or ~1 µg/kg, one to three times daily; split doses favored over one large dose
Timing
Fasted state
Before bed and/or first thing in the morning, and around exercise; separated from carbohydrate meals
Course
8–12 weeks
Defined short or cyclical courses rather than indefinite use; no formal taper required
Time to effect
Growth hormone pulse
15–30 min
Pulse of the body's own growth hormone after an injection
Appetite surge
20–30 min
Hunger peaks 20–30 min post-dose and lasts roughly 30–60 min
Body composition & recovery
Weeks to months
Not well established for GHRP-6 specifically

Benefits

Contraindications
  • Active or recent cancer
  • Uncontrolled diabetes
  • Active proliferative diabetic retinopathy
  • Severe uncontrolled heart failure (NYHA Class III–IV)
  • Pituitary tumors or acromegaly
  • Pregnancy or breastfeeding
  • Children and adolescents (open growth plates)
    •
Key Interactions
  • GHRH and its analogs (sermorelin, tesamorelin, CJC-1295)
  • Other GH secretagogues (GHRP-2, hexarelin, ipamorelin, MK-677/ibutamoren)
  • Corticosteroids (prednisone, dexamethasone)
  • Insulin and glucose-lowering drugs (metformin, sulfonylureas)
  • Thyroid hormone (levothyroxine)
  • OTC agents that raise blood sugar (high-dose niacin, pseudoephedrine)
  • Supplements with additive GH/IGF-1 effect (high-dose arginine, GABA, alpha-GPC)
  • Glucose and appetite supplements (berberine, appetite stimulants)
    •

Risk & Side Effects

  • High: Intense appetite and potential weight gain
    •
  • Medium: Elevated cortisol and prolactin; water retention, joint pain, and carpal tunnel symptoms; impaired glucose tolerance and insulin resistance
    •
  • Low: Contaminated or mislabeled product
    •
  • Speculative: Theoretical cancer-growth concern; long-term safety unknown
    •

Monitoring

Marker Target Why
IGF-1 Upper-middle of age-adjusted normal, not above the reference range Tracks the main downstream effect of raised GH; guards against overshoot and the theoretical cancer risk
Fasting glucose 70–90 mg/dL GH opposes insulin; rising glucose is an early sign of the metabolic downside
HbA1c < 5.4% Captures glucose trend over ~3 months; detects creeping insulin resistance
Fasting insulin 2–5 µIU/mL Detects developing insulin resistance before glucose rises
Prolactin Within normal range, lower half preferred GHRP-6 can raise prolactin at higher doses; chronic elevation affects libido and mood
IGFBP-3 Mid-normal range Complements IGF-1 in assessing GH axis activity

Cadence: Baseline before starting, at 4–8 weeks after starting, then every 3 months during use

Qualitative Assessment

  • Appetite intensity and whether it is helping or harming dietary goals
  • Sleep depth and morning restedness
  • Recovery from exercise and joint comfort (watching for GH-excess joint aches)
  • Energy and mood
  • Any swelling, fluid retention, or tingling/numbness in the hands (carpal tunnel-type symptoms)
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.